氯胺酮
创伤后应激
医学
人口
抗抑郁药
精神科
心理学
临床心理学
焦虑
环境卫生
作者
Rachel Fremont,Oneysha Brown,Adriana Feder,James W. Murrough
出处
期刊:Focus
[American Psychiatric Association Publishing]
日期:2023-07-01
卷期号:21 (3): 257-265
被引量:2
标识
DOI:10.1176/appi.focus.20230006
摘要
Posttraumatic stress disorder (PTSD) is a chronic and debilitating condition. Although several psychotherapeutic and pharmacological treatments are recommended for PTSD, many individuals do not respond to treatment or respond only partially, highlighting a critical need for additional treatments. Ketamine has the potential to address this therapeutic need. This review discusses how ketamine emerged as a rapid-acting antidepressant and has become a potential treatment for PTSD. A single dose of intravenous (IV) ketamine has been shown to facilitate rapid reduction of PTSD symptoms. Repeated IV ketamine administration significantly improved PTSD symptoms, compared with midazolam, in a predominantly civilian sample of individuals with PTSD. However, in a veteran and military population, repeated IV ketamine did not significantly reduce PTSD symptoms. Further study of ketamine as a treatment for PTSD is necessary, including which populations benefit most from this therapy and the potential benefits of combining psychotherapy and ketamine.
科研通智能强力驱动
Strongly Powered by AbleSci AI